Aug 25, 2016
The foundation of any transaction is a negotiation between a buyer and seller around the fair value of an asset. The key to maximizing value in any transaction as a seller or buyer is a robust understanding of an asset’s underlying value. A valuation model is a...
Aug 17, 2016
A simple question plagues every deal maker – ‘Is this a good deal?’ Often it’s a matter of perception, viewed in the context of similar transactions or comparable companies. It can also be evaluated financially with a variety of methods incorporating discounted cash...
Aug 2, 2016
When the financial crisis of 2008 hit and many VCs went out of business, capital available for entrepreneurs with a molecule and a dream dwindled dramatically. The surviving VCs are now much stronger yet bifurcate between early-stage, in which they start the...
Aug 1, 2016
Biopharma markets stabilized in the second quarter of 2016 despite continued global volatility that drove significant declines in the first quarter. Flat markets made investors increasingly selective and limited IPO prospects to companies with significant amounts of...
Jul 25, 2016
Many Japanese pharmaceutical companies are now “global” in terms of scope and size. Companies like Takeda, Astellas, and Daiichi Sankyo have established their commercial footprint around the world. Accordingly, the business development teams at these companies are...
